nodes	percent_of_prediction	percent_of_DWPC	metapath
Droperidol—Amenorrhoea—Vismodegib—skin cancer	0.071	0.0826	CcSEcCtD
Droperidol—Altered state of consciousness—Temozolomide—skin cancer	0.0427	0.0496	CcSEcCtD
Droperidol—Sudden death—Fluorouracil—skin cancer	0.0355	0.0413	CcSEcCtD
Droperidol—Extrapyramidal disorder—Temozolomide—skin cancer	0.0262	0.0304	CcSEcCtD
Droperidol—Amenorrhoea—Temozolomide—skin cancer	0.0224	0.0261	CcSEcCtD
Droperidol—Depression—Imiquimod—skin cancer	0.0183	0.0213	CcSEcCtD
Droperidol—Chills—Vemurafenib—skin cancer	0.0174	0.0202	CcSEcCtD
Droperidol—HTR2A—hindlimb—skin cancer	0.0168	0.129	CbGeAlD
Droperidol—DRD2—nerve—skin cancer	0.0155	0.119	CbGeAlD
Droperidol—Amenorrhoea—Docetaxel—skin cancer	0.0149	0.0173	CcSEcCtD
Droperidol—Chills—Imiquimod—skin cancer	0.0148	0.0172	CcSEcCtD
Droperidol—HTR2A—appendage—skin cancer	0.0144	0.111	CbGeAlD
Droperidol—Bronchospasm—Bleomycin—skin cancer	0.0144	0.0168	CcSEcCtD
Droperidol—Rash—Vismodegib—skin cancer	0.014	0.0163	CcSEcCtD
Droperidol—Dermatitis—Vismodegib—skin cancer	0.014	0.0163	CcSEcCtD
Droperidol—Anaphylactic shock—Vemurafenib—skin cancer	0.0138	0.016	CcSEcCtD
Droperidol—Angioedema—Imiquimod—skin cancer	0.0131	0.0153	CcSEcCtD
Droperidol—Blood pressure increased—Docetaxel—skin cancer	0.0131	0.0152	CcSEcCtD
Droperidol—Syncope—Imiquimod—skin cancer	0.0129	0.015	CcSEcCtD
Droperidol—Hypotension—Vemurafenib—skin cancer	0.0128	0.0149	CcSEcCtD
Droperidol—Palpitations—Imiquimod—skin cancer	0.0127	0.0148	CcSEcCtD
Droperidol—Loss of consciousness—Imiquimod—skin cancer	0.0126	0.0147	CcSEcCtD
Droperidol—Cardiac arrest—Fluorouracil—skin cancer	0.0125	0.0146	CcSEcCtD
Droperidol—Hypertension—Imiquimod—skin cancer	0.0124	0.0144	CcSEcCtD
Droperidol—Anxiety—Imiquimod—skin cancer	0.0122	0.0142	CcSEcCtD
Droperidol—Shock—Imiquimod—skin cancer	0.0115	0.0134	CcSEcCtD
Droperidol—Tachycardia—Imiquimod—skin cancer	0.0114	0.0133	CcSEcCtD
Droperidol—Hyperglycaemia—Temozolomide—skin cancer	0.0111	0.013	CcSEcCtD
Droperidol—Depression—Temozolomide—skin cancer	0.011	0.0128	CcSEcCtD
Droperidol—Body temperature increased—Vemurafenib—skin cancer	0.0109	0.0126	CcSEcCtD
Droperidol—Chills—Bleomycin—skin cancer	0.0105	0.0122	CcSEcCtD
Droperidol—Somnolence—Imiquimod—skin cancer	0.0104	0.0121	CcSEcCtD
Droperidol—HTR2A—nerve—skin cancer	0.0102	0.0786	CbGeAlD
Droperidol—Fenbufen—PTGS2—skin cancer	0.0102	1	CrCbGaD
Droperidol—Hypersensitivity—Vemurafenib—skin cancer	0.0101	0.0118	CcSEcCtD
Droperidol—Hallucination—Temozolomide—skin cancer	0.00984	0.0114	CcSEcCtD
Droperidol—Chills—Dactinomycin—skin cancer	0.00981	0.0114	CcSEcCtD
Droperidol—Body temperature increased—Imiquimod—skin cancer	0.00927	0.0108	CcSEcCtD
Droperidol—Dizziness—Vemurafenib—skin cancer	0.00909	0.0106	CcSEcCtD
Droperidol—Chills—Temozolomide—skin cancer	0.00888	0.0103	CcSEcCtD
Droperidol—HTR2A—endothelium—skin cancer	0.00871	0.0669	CbGeAlD
Droperidol—KCNH2—nipple—skin cancer	0.00868	0.0667	CbGeAlD
Droperidol—Rash—Vemurafenib—skin cancer	0.00867	0.0101	CcSEcCtD
Droperidol—Dermatitis—Vemurafenib—skin cancer	0.00866	0.0101	CcSEcCtD
Droperidol—Hypersensitivity—Imiquimod—skin cancer	0.00864	0.0101	CcSEcCtD
Droperidol—Anaphylactic shock—Bleomycin—skin cancer	0.00833	0.00969	CcSEcCtD
Droperidol—Bronchospasm—Docetaxel—skin cancer	0.00808	0.0094	CcSEcCtD
Droperidol—HTR2A—blood vessel—skin cancer	0.00804	0.0617	CbGeAlD
Droperidol—Angioedema—Temozolomide—skin cancer	0.00787	0.00915	CcSEcCtD
Droperidol—Hypotension—Bleomycin—skin cancer	0.00779	0.00906	CcSEcCtD
Droperidol—Dizziness—Imiquimod—skin cancer	0.00776	0.00902	CcSEcCtD
Droperidol—Palpitations—Temozolomide—skin cancer	0.00761	0.00885	CcSEcCtD
Droperidol—Hypertension—Temozolomide—skin cancer	0.00743	0.00865	CcSEcCtD
Droperidol—Rash—Imiquimod—skin cancer	0.00739	0.0086	CcSEcCtD
Droperidol—Dermatitis—Imiquimod—skin cancer	0.00739	0.00859	CcSEcCtD
Droperidol—Anxiety—Temozolomide—skin cancer	0.00731	0.0085	CcSEcCtD
Droperidol—Anaphylactic shock—Temozolomide—skin cancer	0.00703	0.00818	CcSEcCtD
Droperidol—Body temperature increased—Bleomycin—skin cancer	0.00659	0.00766	CcSEcCtD
Droperidol—Anaphylactic shock—Fluorouracil—skin cancer	0.00648	0.00753	CcSEcCtD
Droperidol—Tachycardia—Fluorouracil—skin cancer	0.00632	0.00735	CcSEcCtD
Droperidol—Somnolence—Temozolomide—skin cancer	0.00625	0.00727	CcSEcCtD
Droperidol—Body temperature increased—Dactinomycin—skin cancer	0.00614	0.00715	CcSEcCtD
Droperidol—Hypersensitivity—Bleomycin—skin cancer	0.00614	0.00714	CcSEcCtD
Droperidol—Hypotension—Fluorouracil—skin cancer	0.00605	0.00704	CcSEcCtD
Droperidol—ADRA1A—epithelium—skin cancer	0.00605	0.0465	CbGeAlD
Droperidol—Chills—Docetaxel—skin cancer	0.0059	0.00687	CcSEcCtD
Droperidol—Somnolence—Fluorouracil—skin cancer	0.00576	0.0067	CcSEcCtD
Droperidol—HTR2A—neck—skin cancer	0.00575	0.0442	CbGeAlD
Droperidol—Hypersensitivity—Dactinomycin—skin cancer	0.00572	0.00666	CcSEcCtD
Droperidol—Body temperature increased—Temozolomide—skin cancer	0.00556	0.00646	CcSEcCtD
Droperidol—Rash—Bleomycin—skin cancer	0.00525	0.00611	CcSEcCtD
Droperidol—Dermatitis—Bleomycin—skin cancer	0.00525	0.0061	CcSEcCtD
Droperidol—Hypersensitivity—Temozolomide—skin cancer	0.00518	0.00602	CcSEcCtD
Droperidol—Syncope—Docetaxel—skin cancer	0.00514	0.00597	CcSEcCtD
Droperidol—Body temperature increased—Fluorouracil—skin cancer	0.00512	0.00595	CcSEcCtD
Droperidol—Palpitations—Docetaxel—skin cancer	0.00506	0.00589	CcSEcCtD
Droperidol—Loss of consciousness—Docetaxel—skin cancer	0.00503	0.00585	CcSEcCtD
Droperidol—Hypertension—Docetaxel—skin cancer	0.00494	0.00575	CcSEcCtD
Droperidol—Rash—Dactinomycin—skin cancer	0.0049	0.0057	CcSEcCtD
Droperidol—Hypersensitivity—Fluorouracil—skin cancer	0.00477	0.00555	CcSEcCtD
Droperidol—Anaphylactic shock—Docetaxel—skin cancer	0.00467	0.00544	CcSEcCtD
Droperidol—ADRA1A—lymphoid tissue—skin cancer	0.00466	0.0358	CbGeAlD
Droperidol—Dizziness—Temozolomide—skin cancer	0.00465	0.00541	CcSEcCtD
Droperidol—Shock—Docetaxel—skin cancer	0.0046	0.00535	CcSEcCtD
Droperidol—Tachycardia—Docetaxel—skin cancer	0.00456	0.00531	CcSEcCtD
Droperidol—Rash—Temozolomide—skin cancer	0.00443	0.00515	CcSEcCtD
Droperidol—Dermatitis—Temozolomide—skin cancer	0.00443	0.00515	CcSEcCtD
Droperidol—Hypotension—Docetaxel—skin cancer	0.00437	0.00508	CcSEcCtD
Droperidol—KCNH2—female reproductive system—skin cancer	0.00434	0.0333	CbGeAlD
Droperidol—Dizziness—Fluorouracil—skin cancer	0.00428	0.00498	CcSEcCtD
Droperidol—Somnolence—Docetaxel—skin cancer	0.00415	0.00483	CcSEcCtD
Droperidol—HTR2A—connective tissue—skin cancer	0.00412	0.0317	CbGeAlD
Droperidol—Rash—Fluorouracil—skin cancer	0.00408	0.00475	CcSEcCtD
Droperidol—Dermatitis—Fluorouracil—skin cancer	0.00408	0.00474	CcSEcCtD
Droperidol—HTR2A—epithelium—skin cancer	0.00391	0.03	CbGeAlD
Droperidol—ADRA1A—head—skin cancer	0.00375	0.0288	CbGeAlD
Droperidol—Body temperature increased—Docetaxel—skin cancer	0.00369	0.0043	CcSEcCtD
Droperidol—DRD2—head—skin cancer	0.00368	0.0283	CbGeAlD
Droperidol—KCNH2—head—skin cancer	0.00363	0.0279	CbGeAlD
Droperidol—Hypersensitivity—Docetaxel—skin cancer	0.00344	0.00401	CcSEcCtD
Droperidol—Dizziness—Docetaxel—skin cancer	0.00309	0.0036	CcSEcCtD
Droperidol—Rash—Docetaxel—skin cancer	0.00295	0.00343	CcSEcCtD
Droperidol—Dermatitis—Docetaxel—skin cancer	0.00294	0.00342	CcSEcCtD
Droperidol—HTR2A—female reproductive system—skin cancer	0.00291	0.0223	CbGeAlD
Droperidol—KCNH2—lymph node—skin cancer	0.00254	0.0195	CbGeAlD
Droperidol—HTR2A—head—skin cancer	0.00243	0.0186	CbGeAlD
